There's big money in biotech in the Greater Boston area. Last year, venture capital firms invested more than $3 billion in the state's biotech and pharmaceutical companies, according to the Massachusetts Biotechnology Council. The amount has risen every year since 2012. Local companies have already produced revolutionary treatments for rare diseases, cancer and more. And there's promise and hope for cures and treatments still to come. Because of that, there's no shortage of capital.Biotech companies often go public even if they haven't yet put a product on the market, let alone turned a profit. MIT finance professor Andrew Lo says there's good reason for so much exuberance.
Life happens on social media first. When North Korea fires a ballistic missile, Korean news agencies tweet about it. When President Donald Trump has a beef with Amazon.com (ticker: AMZN) – or anyone, really – he tweets about it. Social media is becoming "a place where decision-makers go to share information," says Adela Quinones, news product manager at Bloomberg LP in New York. From public figures to company spokesmen, people are increasingly using social media to update the world about events that affect stock markets.
“Nobody’s talking about this story,” Max Tokarsky said. Not exactly true, as the founder and CEO of InvestAcure is telling anyone who will listen. A former non-profit executive-turned-evangelist for the Impact Investment and Public Benefit Corporation model, Tokarsky is slated to present the keynote address at the Alzheimer's-2018 International Conference in Rome, Italy May 8. The Rome conference brings together researchers from around the world focused on groundbreaking research to slow, reverse or prevent dementia and Alzheimer’s disease. A life-long social entrepreneur and former non-profit executive, Tokarsky will present "The Enigma of Eroom’s Law and The Wall Street Math Stifling Alzheimer’s Drug Discovery" in Rome. He wants to talk about funding a cure for Alzheimer’s disease. But he’s not talking about just asking major corporations or the government or even Big Pharma for help. Tokarsky wants everyone to pitch in. And he’s figured out a way we can.
Buying a stock is one thing, but when do you sell? That question will have been nagging many nervous investors in recent months, after watching global stock markets tumble. One potential solution is to use stop-loss orders that ensure you exit your position when the price falls below a designated point. Do stop-loss orders work? Can they help investors sleep better at night by cutting back on risk? Or are stops a trader’s tool, best left to those who nip in and out of markets rather than investors with multiyear horizons?
Economist Andrew Lo talks to the FT's John Authers about his adaptive markets hypothesis, the idea that markets develop and adapt over time and should be modelled using concepts from biology instead of physics. It's the subject of his recent book, Adaptive Markets: Financial Evolution at the Speed of Thought.
Andrew W. Lo, director of the MIT Laboratory for Financial Engineering and the Charles E. and Susan T. Harris Professor at MIT, describes his research on artificial intelligence and financial markets at the launch event for the MIT Intelligence Quest, an Institute-wide initiative on human and machine intelligence research, its applications, and its bearing on society.
Derek Lowe's commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of Science Translational Medicine. All content is Derek’s own, and he does not in any way speak for his employer.
How do you drive investors to spend money on cutting-edge cancer treatments? One idea, according to economist Andrew Lo, is to sell securities in a megafund of research projects. Economics correspondent Paul Solman explores how financial engineering could be the starting point for curing cancer.